Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones.
On the basis of adverse events reported to the US Food and Drug Administration, it was observed that atorvastatin-associated adverse event reports were 3.1 times more likely to list rosiglitazone or pioglitazone as a concomitant medication compared with simvastatin-associated adverse event reports.
Alsheikh-Ali
Alawi A
AA
Department of Medicine, Division of Cardiology, Preventive Cardiology Center, Tufts-New England Medical Center, 750 Washington Street, Boston, MA 02111, USA.
Karas
Richard H
RH
D016907:Adverse Drug Reaction Reporting Systems; D000368:Aged; D000069059:Atorvastatin; D016208:Databases, Factual; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D000077205:Pioglitazone; D011758:Pyrroles / Q000008:administration & dosage / Q000009:adverse effects*; D000077154:Rosiglitazone; D019821:Simvastatin / Q000008:administration & dosage / Q000009:adverse effects*; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration
D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D011758:Pyrroles; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000069059:Atorvastatin; D019821:Simvastatin; D000077205:Pioglitazone